Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
This is not a financial advice!
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Massive block buys!
We need to break 9.0.
Keep an eye on 13.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains.
SL under 5.7
TP approx. 15.0
Most info on the chart.
Trade carefully!